PARP1 blockade is synthetically lethal in XRCC1 deficient sporadic epithelial ovarian cancers

Reem Ali(Hamad bin Khalifa University), Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust), Islam M. Miligy(University of Nottingham), Adel Alblihy(University of Nottingham), Paul M. Moseley(Nottingham University Hospitals NHS Trust), Katia A. Mesquita(University of Nottingham), Stephen Chan(Heidelberg University), Muslim Alabdullah(Islamic Azad University, Science and Research Branch), Emad A. Rakha(Nottingham University Hospitals NHS Trust)
Cancer Letters
October 24, 2019
10.1016/j.canlet.2019.10.035
Cited by 36

Related Papers

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
|The Lancet|2022|664
Prospective Randomized Trial of Docetaxel Versus Doxorubicin in Patients With Metastatic Breast Cancer
|Journal of Clinical Oncology|1999|639
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
|The Lancet Oncology|2013|605
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial
|The Lancet Oncology|2014|374